Conditions: Traumatic Brain INjury
Keywords: Attention Traumatic Brain INjury Atomoxetine Strattera
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 60
Healthy volunteers: no

Brief summary:
Atomoxetine is the only medication that is currently approved by the FDA for the treatment of attention deficit hyperactivity disorder in adults. It has gained recent interest as an alternative medication for treating attentional problems related to traumatic brain injury (TBI), but it's effectiveness in this population has not been studied. There are a number of advantages of Atomoxetine over traditional neuro-stimulant medications currently used for attentional disorders after traumatic brain injury. This study will use a randomized double-blind placebo-controlled crossover design to investigate the efficacy of atomoxetine to improve attention, behavioral function, and depression in adults with TBI

Detailed description:

Arms:
arm 1: 40mg atomoxetine twice a day for 2 weeks arm 2: Placebo twice a day for two weeks

Interventions: intervention 1: atomoxetine intervention 2: placebo
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: